ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

John Schieszer

John Schieszer

Posts by Author

The FDA on March 23, 2017, granted accelerated approval to avelumab (Bavencio) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma.

Quantitative morphological features of tumor pathological images may help predict prognosis in patients with non-small cell lung cancer.

A new population-based study is suggesting that there are significant racial disparities in gene expression profiling testing in women with breast cancer.

Researchers at the NYU Langone Medical Center’s Perlmutter Cancer Center have discovered multiple somatic mutations and copy-number alterations in UCS tumors that offer expanded therapeutic options.

Researchers at the Mayo Clinic are reporting that they have identified a new therapy that shrinks tumors in patients with multiple myeloma.

Investigators at University of California, Irvine report that they have uncovered a specific mutation in the ATR gene that allows melanoma tumor cells to remain undetected by the immune system.

A new study is suggesting that serial genetic changes at the KRAS locus are frequent in cancer and modulate competitive fitness and MEK dependency.

Researchers at the University of Illinois and collaborators in China have found a way to tag and target elusive cancers with small-molecule sugars by hijacking a cancer cell’s own metabolism.

A research team from the United States and Canada have developed and successfully tested new computational software that determines whether a human DNA sample includes an epigenetic add-on linked to cancer and other adverse health conditions.

California researchers are now suggesting that analyzing copies of genes may point to new treatments for ovarian cancer as well as for other tumor types. The researchers contend that targetable genetic changes in tumors should not be limited to mutations.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.